Radiochemotherapy combined with regional pelvic hyperthermia induces high response and resectability rates in patients with nonresectable cervical cancer > or =FIGO IIB „bulky“
/in Cervical Cancer, International Publications /von 2006-09-18 / Int. J. Radiat. Oncol. Biol. Phys. 2006 Nov;66(4):1159-67Noninvasive magnetic resonance thermography of soft tissue sarcomas during regional hyperthermia: correlation with response and direct thermometry
/in Hyperthermia, International Publications, Soft Tissue Sarcoma /von 2006-09-15 / Cancer 2006 Sep;107(6):1373-82Patient-specific dendritic-cell vaccines for metastatic melanoma
/in International Publications, Malignant Melanoma /von 2006-09-14 / N. Engl. J. Med. 2006 Sep;355(11):1179-81Heat shock treatment of tumor lysate-pulsed dendritic cells enhances their capacity to elicit antitumor T cell responses against medullary thyroid carcinoma
/in Dendritic Cells, International Publications, Thyroid Cancer /von 2006-09-05 / J. Clin. Endocrinol. Metab. 2006 Nov;91(11):4571-7Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers
/in Dendritic Cells, International Publications, Thyroid Cancer /von 2006-09-01 / Endocr. Relat. Cancer 2006 Sep;13(3):779-95[Immunotherapeutic effects of beta-elemene combined with interleukin-23 gene-modified dendritic cells on murine pancreatic carcinoma]
/in International Publications, Pancreatic Cancer /von 2006-09-01 / Ai Zheng 2006 Sep;25(9):1082-6Basic overview of current immunotherapy approaches in urologic malignancy
/in International Publications, Prostate Cancer /von 2006-09-01 / Urol. Oncol. 2006 Sep-Oct;24(5):413-8Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells
/in International Publications, Prostate Cancer /von 2006-09-01 / Urol. Oncol. 2006 Sep-Oct;24(5):434-41Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity
/in International Publications, Malignant Melanoma /von 2006-09-01 / J. Immunother. 2006 Sep-Oct;29(5):545-57
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution